Clinical trials: Combined Advanced Targeted Therapy
Targeted Therapy, Chemotherapy
Donafenib for Recurrent Cervical Cancer
This study is to evaluate the safety and tolerability of Donafenib combined with paclitaxel and platinum ± programmed death 1 monoclonal antibody (PD-1 antibody) in patients with recurrent cervical cancer.
- Conditions
- Targeted Therapy, Chemotherapy, Recurrent Cervical Carcinoma, Metastatic Cervical Carcinoma
- Trial name
- NCT05310331
- Testing
- Donafenib combined with paclitaxel and platinum ± PD-1 antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Lei Li
Ovarian Cancer
Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib
In this study, investigators propose to use fuzuloparib and apatinib as neoadjuvant therapy for Homologous recombination deficiency （HRD）positive advanced ovarian cancer patients, aiming to explore the efficacy and safety of this…
- Trial name
- NCT07033819
- Testing
- Neoadjuvant therapy with fuzuloparib in combination with apatinib, Preoperative Period, Chemotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Metastatic Colorectal Cancer
Dual Targeting of Vascular Endothelial Growth Factor-A Together With Angiopoietins in Chemotherapy-naïve Metastatic Colorectal Cancer
This is a clinical trial investigating the effectiveness and safety of the combination of the study drugs bevacizumab and AMG386 in patients with advanced (metastatic) chemotherapy-naive bowel (colorectal) cancer.
- Trial name
- Vengeance (NCT01249521)
- Testing
- AMG386 and bevacizumab
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Austin Health
HR+/HER2- Advanced Breast Cancer, Targeted Therapy
Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer
To explore the efficacy and safety of chidamide combined with endocrine in phosphoinositide-3-kinase,catalytic,alpha gene(PI3KCA) wild type hormone receptor positive(HR+)/human epidermal growth factor receptor 2 negative (HER2-)…
- Trial name
- NCT05983107
- Testing
- Everolimus, Chidamide, Endocrine therapy
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Solid Tumor
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
BBI-825 is a potent, selective, oral, small molecule inhibitor of ribonucleotide reductase (RNR). This is a first-in-human, open-label, non-randomized, 3-part, Phase 1/2 study to determine the safety profile and identify the…
- Trial name
- STARMAP (NCT06299761)
- Testing
- BBI-825
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Boundless Bio, Inc.
Advanced Liver Cancer
Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer
Liver cancer is a common malignant tumor in China, and its incidence rate ranks third and remains high. The treatment of liver cancer has made some progress in recent years, mainly the progress of radical treatment such as…
- Trial name
- NCT04163237
- Testing
- PD-1, Sorafenib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangxi Medical University
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma
This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-Targeting ADC) in combination with Pucotenlimab and Cisplatin as neoadjuvant therapy for patients with locally advanced head and neck…
- Trial name
- NCT07393477
- Testing
- Combination Therapy with Becotatug Vedotin, Pucotenlimab, and Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sir Run Run Shaw Hospital
Locally Advanced Rectal Cancer (LARC)
Short-Course Online Adaptive Radiotherapy Combined With Chemotherapy, Targeted Therapy and Immunotherapy as Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer
Standard treatment for patients with proficient mismatch repair (pMMR) / microsatellite stable (MSS) locally advanced rectal cancer (LARC) consists primarily of neoadjuvant chemoradiotherapy followed by radical surgery.
- Trial name
- NCT07581626
- Testing
- SCRT+targeted therapy+immunotherapy+chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Metastatic Renal Cell Carcinoma
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment
This is an open-label, multicenter, Phase 1b/2 study of lenvatinib alone and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior VEGF-targeted treatment.
- Trial name
- NCT01136733
- Testing
- Lenvatinib, Everolimus
- Where
- 37 sites in United States, Czechia and 3 more
- Volunteers
- 173 people
- Sponsor
- Eisai Inc.
Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection
Combination Therapy of L19IL2 and Gemcitabine in Advanced Pancreatic Cancer Patients
Systemic treatment for advanced, non-resectable pancreatic cancer still having minimal impact on the survival of patients. Even with the application of more potent gemcitabine-based regimens, survival of more than 1 year is…
- Trial name
- NCT01198522
- Testing
- L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine
- Where
- 5 sites in Germany, Italy
- Volunteers
- 28 people
- Sponsor
- Philogen S.p.A.
HER2-positive Breast Cancer
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
The purpose of this study was to evaluate the efficacy and safety of pyrotinib combined with trastuzumab and albumin paclitaxel in first-line treatment of HER2-positive advanced or metastatic breast cancer.
- Trial name
- NCT05429294
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 209 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Advanced Colorectal Carcinoma
Fruquintinib and Raltitrexed Versus Fruquintinib Monotherapy in Advanced Colorectal Cancer
A randomized, controlled phase II clinical trial of Fruquintinib combined with Raltitrexed versus Fruquintinib monotherapy in patients with advanced colorectal cancer who had failed second-line or above standard chemotherapy
- Trial name
- NCT04582981
- Testing
- Fruquintinib and raltitrexed, Fruquintinib
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Fudan University
Gastric or Gastroesophageal Junction Adenocarcinoma
The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase II Study Evaluating the Efficacy and Safety of LM-302 in Combination with Candonilimab and Capecitabine for First-Line Treatment in Patients with Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric…
- Trial name
- NCT06587425
- Testing
- LM-302+Candonilimab+Capecitabine
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
At present, there is no standard treatment plan for hepatocellular carcinoma after the progress of first-line target immunotherapy.
- Trial name
- NCT07078305
- Testing
- Regorafenib and tislelizumab, Regorafenib
- Volunteers
- 134 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
This phase Ib trial studies the dose and schedule of 177Lu-PSMA-617 and pembrolizumab in treating persons with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma
- Trial name
- NCT03805594
- Testing
- Lutetium Lu 177-PSMA-617, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Francisco
HCC - Hepatocellular Carcinoma
EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial
The goal of this clinical trial is to evaluate the efficacy and safety of combining endovascular denervation (EDN) with transarterial chemoembolization/ hepatic arterial infusion chemotherapy (TACE/HAIC) plus second-line…
- Trial name
- NCT07187284
- Testing
- EDN combined with TACE/HAIC and Immuno-Targeted Therapy, TACE/HAIC plus Immuno-Targeted Therapy
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Zhongda Hospital
Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
Background: The protein mesothelin is found on many kinds of tumors. The drug LMB-100 targets cancer cells that make this protein. Researchers want to see if LMB-100 combined with another drug can help people with these tumors.
- Conditions
- Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic
- Trial name
- NCT04034238
- Testing
- LMB-100, Tofacitinib, Mesothelin Expression
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Neoplasia
Exploratory Clinical Study of Claudin18.2-Targeted CAR-DC and CAR-T Therapy in Advanced Colorectal Cancer
This is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of Claudin18.2-targeted CAR-DC combined with CAR-T cell therapy in patients with advanced colorectal cancer.
- Trial name
- NCT06946615
- Testing
- Claudin18.2-targeted CAR-T Cells, Claudin18.2-targeted CAR-DCs
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer, Metastastic Breast Cancer
Culmerciclib in HR+/HER2+ Advanced Breast Cancer
This is a phase II, multicenter, open-label, single-arm clinical study. The purpose of this study is to evaluate the efficacy and safety of culmerciclib combined with anti-HER2 targeted therapy and endocrine therapy as…
- Conditions
- Breast Cancer, Metastastic Breast Cancer, HER2+ Advanced Breast Cancer
- Trial name
- NCT07732491
- Testing
- Culmerciclib
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Esophageal Cancer, Biliary Tract Cancer
Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer
In this study, non-operable esophagogastric adenocarcinoma cancer patients or non-operable biliary cancer patients whose cancer progressed/spread/got worse after first line treatment will be treated with or without immunotherapy…
- Conditions
- Esophageal Cancer, Biliary Tract Cancer, GastroEsophageal Cancer, Hepatobiliary Neoplasm
- Trial name
- DYNAMIC (NCT03818997)
- Testing
- DKN-01, Atezolizumab, Paclitaxel
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC